Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd. and founder Joseph Edelman have filed a Schedule 13G disclosing a passive stake in Praxis Precision Medicines (PRAX).
- Shares owned: 1,362,503 common shares.
- Ownership percentage: 6.69 % of the 20,368,982 shares outstanding as of 30 Apr 2025.
- Control rights: The Reporting Persons hold shared voting and dispositive power over all shares; they report zero sole voting/dispositive power, indicating no unilateral control.
- Date of event: 15 Jul 2025; filing signed 22 Jul 2025.
- Filer status: Perceptive Advisors is an investment adviser (IA); Edelman is a U.S. individual; Master Fund is Cayman-based.
The certification states the securities were not acquired to influence control, confirming a passive investment posture. Perceptive’s >5 % position may draw investor attention because the healthcare-focused fund is considered a sophisticated life-sciences investor.
Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Dean J. Mitchell received a new stock option grant for 10,520 common shares on 26 June 2025. The option carries an exercise price of $44.04 and expires on 26 June 2035. Vesting occurs in twelve equal monthly installments over one year starting on the grant date. No common shares were bought or sold; this is purely an equity-based compensation award that increases Mr. Mitchell’s derivative holdings to 10,520 options, all held directly. The transaction is routine and designed to align director incentives with shareholder interests, with minimal immediate balance-sheet or ownership impact on PRAX.
Praxis Precision Medicines (PRAX) – Form 4 Insider Activity
Director William D. Young disclosed the grant of a stock option for 10,520 common shares on 26-Jun-2025 at an exercise price of $44.04. The option vests in twelve equal monthly installments over one year, beginning on the grant date, and expires on 26-Jun-2035. No open-market purchases or sales of common stock were reported. Following the transaction, Mr. Young beneficially owns 10,520 derivative securities linked to PRAX common shares. The filing was executed on 27-Jun-2025.
Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Gregory Norden received an option grant on 26 Jun 2025.
- Derivative security issued: Non-qualified stock option covering 10,520 common shares with an exercise price of $44.04.
- Vesting schedule: Vests in twelve equal monthly instalments beginning 26 Jun 2025, fully vested after one year.
- Expiration: 26 Jun 2035 (10-year term).
- Ownership impact: Following the grant, Norden beneficially owns 10,520 derivative securities (stock options) directly; no non-derivative share movement is reported.
The filing represents a routine equity incentive award to a board member and does not indicate any open-market purchase or sale of PRAX shares.
Praxis Precision Medicines, Inc. (PRAX) — Form 4 insider filing
Director Jill DeSimone received a new option grant on 26 June 2025. The grant covers 10,520 shares of common stock at an exercise price of $44.04 and expires on 26 June 2035. Vesting is scheduled in twelve equal monthly installments over one year beginning on the grant date, aligning compensation with near-term company performance. After this transaction Ms. DeSimone holds 10,520 derivative securities directly. No common-stock transactions, sales, or additional option exercises were reported.
The filing represents a routine equity incentive for a non-employee director and does not change PRAX’s share count in a material way. The transaction code "A" confirms an acquisition of options rather than an open-market purchase, so immediate cash outlay or insider buy-signal implications are minimal.
Praxis Precision Medicines, Inc. (PRAX) reported a routine insider equity award through a Form 4 filed on 27 June 2025. Director Jeffrey Chodakewitz received a grant of 10,520 stock options on 26 June 2025 at an exercise price of $44.04 per share. The options vest in 12 equal monthly installments over one year beginning the grant date and carry an expiration date of 26 June 2035. No open-market purchases or sales of common stock were disclosed, and Mr. Chodakewitz’s direct derivative holdings after the transaction total 10,520 options. The filing reflects a standard compensation-related award rather than a change in the director’s economic exposure to outstanding common shares.
Praxis Precision Medicines, Inc. (PRAX) – Form 4 Insider Transaction
Director Merit Ester Cudkowicz reported the grant of 10,520 stock options on 26 June 2025. The options carry an exercise price of $44.04 and expire on 26 June 2035. Ownership is recorded as direct.
Vesting schedule: the award vests in 12 equal monthly installments over one year, beginning 26 June 2025, resulting in full vesting by 26 June 2026. Following the grant, the reporting person beneficially owns 10,520 derivative securities; no common-stock transactions were disclosed in Table I.
The filing is routine compensation-related and does not involve any sale or purchase of shares. It primarily signals ongoing alignment of director incentives with shareholder interests and does not immediately affect PRAX’s capital structure, earnings, or liquidity.
Praxis Precision Medicines, Inc. (Nasdaq: PRAX) filed a Form 8-K detailing the voting results from its 2025 Annual Meeting held on June 26, 2025. A quorum was present and all three management proposals passed.
- Proposal 1 – Election of Class II Directors: Dr. Jeffrey Chodakewitz was elected with 14,596,188 votes for and 2,998,186 withheld; Dr. Merit Cudkowicz received 17,499,300 votes for and 95,074 withheld. Both directors will serve until the 2028 annual meeting. Broker non-votes for each nominee totaled 778,152.
- Proposal 2 – Auditor Ratification: Ernst & Young LLP was re-appointed as independent registered public accounting firm for FY 2025 with 18,358,636 votes for, 7,630 against and 6,260 abstentions (no broker non-votes).
- Proposal 3 – Say-on-Pay (advisory): Executive compensation was approved with 10,671,320 votes for, 6,919,705 against, 3,349 abstentions and 778,152 broker non-votes.
No additional matters were brought before stockholders. The filing is primarily administrative and does not disclose financial performance, transactions, or strategic changes.